INVESTOR RELATIONS

2016 News

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/19/16NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 19, 2016-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases today announced that the company will be hosting an Investor/Analyst Day on January 8th in San Francisco. NantKwest will be sharing with ... 
Printer Friendly Version
12/12/16NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced that the company presented results from a preclinical study on the company’s high affinity Natural Killer (haNK) cell therapy program at the S... 
Printer Friendly Version
11/28/16NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016. NantKwest’s presentation will include a business overview and clinical update. Details are below: Piper Jaffray 28th Annual Healthcar... 
Printer Friendly Version
11/22/16Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the Company’s abstract reviewing data on the company’s CD19.taNK program has been accepted for an oral presentation at the upcoming... 
Printer Friendly Version
11/22/16NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced in a paper published today in the journal Oncotarge... 
Printer Friendly Version
11/14/16NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat can... 
Printer Friendly Version
11/08/16NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin Lymphoma CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 8, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing ... 
Printer Friendly Version
11/03/16NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology
Presentation of Combination Therapy with a CS1.taNK and Daratumumab in Multiple Myeloma Presentation of Activated Natural Killer Cell Therapy (aNK) in Acute Myeloid Leukemia Presentation of Preclinical Data of a CD19.taNK Targeting Non-Hodgkin LymphomaCulver City, November 3, 2016 NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, ... 
Printer Friendly Version
10/04/16Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer
Cancer Breakthroughs 2020 milestone: novel-novel combination of GPS Cancer guided cell based NK cell therapy and fusion proteins in QUILT trial CULVER CITY, Calif. & MIRAMAR, Fla.--(BUSINESS WIRE)--Oct. 4, 2016-- Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases and NantKwest Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the unique power of off-the-shelf Natural Killer (N... 
Printer Friendly Version
10/03/16NantKwest Announces Presentations at the Upcoming 16th Annual Meeting of the Society for Natural Immunity
CULVER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2016-- NantKwest, Inc (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the company has been selected to present at NK2016, the 16th Annual Meeting of the Society for Natural Immunity in Taormina, Italy o... 
Printer Friendly Version
09/10/16NantKwest Announces Presentations at Upcoming Investment Conferences
CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2016-- NantKwest, Inc (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the company will be presenting at two investment conferences in September: The Rodman & Renshaw 2016 Global Healthcare Conferen... 
Printer Friendly Version
05/17/16NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Breakthroughs 2020 Initiative
CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company's aNK, haNK and taNK clinical programs in a presentation at the Bank of America Merrill Lynch 2016 Health Ca... 
Printer Friendly Version
05/09/16DR. PATRICK SOON-SHIONG TO GIVE KEYNOTE ADDRESS AND NANTKWEST TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH 2016 HEALTH CARE CONFERENCE
Culver City, May 6, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest's Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016.   NantKwest's presentation will be at 1:00 pm PT and will include an update and business overview by company management. The webcast will be accessible on the Investor Re... 
Printer Friendly Version
04/15/16NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Positive Preclinical Data Of The First "Off The Shelf," GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics CULVER CITY, Calif. – April 15, 2016 - NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced th... 
Printer Friendly Version
04/05/16NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies
Culver City, California, April 5, 2016—NantBioScience, Inc., is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor, independent of the cancer’s anatomical type. NantKwest, Inc. (Nasdaq: NK), an affiliate of NantBioScience, is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infec... 
Printer Friendly Version
03/22/16Partnership enables rapid and efficient start-up of 15,000 research sites nationwide
CULVER CITY, Calif. – March 22, 2016 – Cancer Breakthroughs 2020, the nation's most comprehensive cancer collaborative initiative formed to accelerate next-generation immunotherapy in cancer, announced today the selection of Schulman IRB as its national institutional review board (IRB) of record. Schulman will provide review services for Cancer Breakthroughs 2020's Quantitative Integrative Lifelong Trial (QUILT) program, which aims to test multiple combinations of therapies on up to 20,000 pati... 
Printer Friendly Version
03/04/16NantKwest and NantHealth to Present at the Cowen and Company’s 36th Annual Healthcare Conference
... 
Printer Friendly Version
03/03/16San Diego key part of program to beat cancer by 2020
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowessBy Bradley J. Fikes (/staff/bradley-fikes/) | 3:33 p.m. March 3, 2016If physician turned billionaire biotech entrepreneur Dr. Patrick Soon-Shiong succeeds in his ambitious goal to defeat cancer by 2020, San Diego County's dynamic biotech industry is likely to play an important role.San Diego offers talented people and good infrastructure and good quality of life, Soon-Shiong said in a Thursday interview. That makes it an im... 
Printer Friendly Version
02/24/16Patrick Soon-Shiong, MD, to Deliver Cancer Breakthroughs 2020 Keynote at Biocom Global Life Science Partnering Conference
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, LLC, and leader of the Cancer Breakthroughs 2020 program, will deliver the keynote session, "Cancer Breakthroughs 2020 & The National Immunotherapy Coalition," at the sixth annual Biocom Global Life Science Partnering Conference, an exclusive partnering forum from February 24-25, 2016 at The Lodge at Torrey Pines in La Jolla, California. Biocom will bring together leaders from pharmaceutical and biotec... 
Printer Friendly Version
02/22/16Nant Leaders to Share Vision of Cancer Breakthroughs 2020 Program at Premier Oncology Event
Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer) Phoenix – February 22, 2016 – NantWorks, LLC, NantKwest (Nasdaq: NK), and NantHealth, LLC  today announced the scheduled discussion topics at the eighth annual Cancer Center Business Summit, a premier oncology event with this year's theme, "Oncology Care Transformation: What's Working and What Lies Ahead." The Cancer Center Business Summit w... 
Printer Friendly Version